Corvus Pharmaceuticals Inc

NASDAQ:CRVS   3:59:53 PM EDT
4.48
-0.31 (-6.47%)
Products, Regulatory

Corvus Pharmaceuticals Updates On Mupadolimab Programs In Oncology And Infectious Disease

Published: 09/22/2021 10:16 GMT
Corvus Pharmaceuticals Inc (CRVS) - Corvus Pharmaceuticals Provides Updates on Mupadolimab (anti-cd73) Programs in Oncology and Infectious Disease.
Corvus Pharmaceuticals Inc - Covid-19 Study Immune Response Data Found to Be Consistent With Proposed Mechanism.
Corvus Pharmaceuticals - Oncology Phase 1b/2 Clinical Trial Enrolling Patients With Head and Neck Cancers and Patients With Lung Cancer.
Corvus Pharmaceuticals Inc - Oncology Phase 1b/2 Clinical Trial Data Anticipated at Sitc Meeting in November.
Corvus Pharmaceuticals - Results Suggest Improvement in Primary, Key Secondary Endpoints in Patients Treated With Single Doses of Mupadolimab at 2mg/kg & 1mg/kg Versus Placebo.
Corvus Pharmaceuticals - No Drug Related Adverse Events Were Reported in Phase 3 Clinical Trial of Mupadolimab for Covid-19.